Wells Fargo & Company Theravance Biopharma, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TBPH
# of Institutions
122Shares Held
47.3MCall Options Held
200Put Options Held
12.8K-
Madison Avenue Partners, LP New York, NY9.51MShares$90.5 Million9.44% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$71 Million1.94% of portfolio
-
Newtyn Management, LLC New York, NY4.5MShares$42.8 Million6.4% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$36 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$26.3 Million1.95% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $636M
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...